AAVantgarde announces 3 oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting in Rome

October 8, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces three oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting (ESGCT), to be held October 22-25 in Rome. AAVantgarde is validating its platform technology in two inherited retinal diseases with clear unmet need, with Usher syndrome type 1B already in the clinic and Stargardt advancing towards clinical development.

At this conference, we will be presenting NHP preclinical data from our Stargardt’s program and the process development, analytics and manufacture of the dual vectors to enable the clinical supply for our programs. In addition, our Scientific Founder, Professor Alberto Auricchio, TIGEM Scientific Director, will give a presentation on expediting AAV-based gene therapies.

Oral Presentations details:

Presentation Date/Time: Tuesday 22 October 2024, 14.00-16.30 h CEST
Session title: ExpEditing AAV gene Therapy
Session Room: Plenary Hall
Final abstract number: INV01

Presentation Date/Time: Tuesday 22 October 2024, 17.00-19.30 h CEST
Session title: Safety and expression of intein-based Dual AAV8.ABCA4 in the non-human-primate retina
Session Room: Meeting room 2
Final abstract number: OR017

Presentation Date/Time: Friday 25 October 2024, 11.00 – 13.00 h CEST
Session title: Production of dual AAV vectors for the delivery of large genes
Session Room: Plenary Hall
Final abstract number: INV73